Effects of risedronate and alfacalcidol on parameters of atherosclerosis in type 2 diabetes patients with osteoporosis.

Trial Profile

Effects of risedronate and alfacalcidol on parameters of atherosclerosis in type 2 diabetes patients with osteoporosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2009

At a glance

  • Drugs Alfacalcidol (Primary) ; Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Jun 2009 New trial record
    • 22 Jun 2009 Results reported in UMIN registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top